Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.
C. Grassos,Maria Marketou,Neil Chapman,S. Saeed,Jorge Polonia,Florian P Limbourg,J. Fauvel,P. Zebekakis,P. Sarafidis,L. Ruilope,Guido Grassi,Alberto Mazza,L. Rump,S. Lueders,Franco Veglio,Tine De Backer,Béatrice Duly-Bouhanick,S. Rubin,S. Cottone,J. Huart,Giacomo Pucci,Dimitris Papadopoulos,H. Triantafyllidi,Anna Oliveras,A. Manolis,M. Viigimaa,Philippe Delmotte,R. Kreutz,G. Wuerzner,A. Persu,Daniel Gordin,J. Václavík,G. Stergiou,Thilo Burkard,Dominique Guerrot,F. Mallamaci,V. Paixão-Dias,I. Tengiz,J.-M. Halimi,Fernando Jaén Águila,Jaap Deinum,M. Camafort,Peter Nilsson,M. Muiesan,R. Schmieder,Z. Járai,Riccardo Sarzani,Pierre Fesler,G. Bilo,Thomas Weber,Gert Mayer,O. Ormezzano,I. Papadakis,P. van der Niepen,Raffaele Izzo,Michel Azizi,N. R. Robles,I. Kantola,M. Doumas,M. Lopez-sublet,P. Zelveian,M. van der Giet,R. Venzin,Konstontinos Tsioufis,M. Solbu,L. Vogt,F. Silhol,Zbigniew Gaciong,Miroslav Souček,Thomas Kahan,Edgar Nasr,E. Kociánová,Iain Macintyre,E. Gkaliagkousi,Sabine Perl,Isabella Sudano,M. Dorobantu,R. Tabbalat,E. Sanidas,R. Pontremoli,Jean-Jacques Mourad,Michael Bursztyn,S. Sokolovic,Rainer Dusing,J. Widimský
DOI: https://doi.org/10.1097/HJH.0000000000003756
IF: 4.9
2024-05-14
Journal of Hypertension
Abstract:OBJECTIVE
Real-life management of hypertensive patients with chronic kidney disease (CKD) is unclear.
METHODS
A survey was conducted in 2023 by the European Society of Hypertension (ESH) to assess management of CKD patients referred to ESH-Hypertension Excellence Centres (ESH-ECs) at first referral visit. The questionnaire contained 64 questions with which ESH-ECs representatives were asked to estimate preexisting CKD management quality.
RESULTS
Overall, 88 ESH-ECs from 27 countries participated (fully completed surveys: 66/88 [75.0%]). ESH-ECs reported that 28% (median, interquartile range: 15-50%) had preexisting CKD, with 10% of them (5-30%) previously referred to a nephrologist, while 30% (15-40%) had resistant hypertension. The reported rate of previous recent (<6 months) estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) testing were 80% (50-95%) and 30% (15-50%), respectively. The reported use of renin-angiotensin system blockers was 80% (70-90%). When a nephrologist was part of the ESH-EC teams the reported rates SGLT2 inhibitors (27.5% [20-40%] vs. 15% [10-25], P = 0.003), GLP1-RA (10% [10-20%] vs. 5% [5-10%], P = 0.003) and mineralocorticoid receptor antagonists (20% [10-30%] vs. 15% [10-20%], P = 0.05) use were greater as compared to ESH-ECs without nephrologist participation. The rate of reported resistant hypertension, recent eGFR and UACR results and management of CKD patients prior to referral varied widely across countries.
CONCLUSIONS
Our estimation indicates deficits regarding CKD screening, use of nephroprotective drugs and referral to nephrologists before referral to ESH-ECs but results varied widely across countries. This information can be used to build specific programs to improve care in hypertensives with CKD.
Medicine